Valaciclovir prophylaxis versus preemptive valganciclovir for the prevention of cytomegalovirus inclusion disorders in renal transplant recipients
Phase of Trial: Phase II
Latest Information Update: 08 Jun 2016
At a glance
- Drugs Valaciclovir (Primary) ; Valganciclovir
- Indications Cytomegalic inclusion disorders
- Focus Biomarker; Therapeutic Use
- 04 May 2011 Long-term results presented at the American Transplant Congress -- 11th Joint Congress of the American Society of Transplant Surgeons and the American Society of Transplantation.
- 05 Nov 2010 New trial record.